Please login to the form below

trial failures

This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

combination. MET is known as a resistance mechanism for EGFR-positive NSCLC, and Merck also has a trial on the go of tepotinib plus Tagrisso in this setting. ... ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of

Latest news

Northsea Therapeutics raises $40m to develop fish oil NASH drug

Looking for mid-stage trial success in field littered with failures. Following in Amarin’s footsteps, Dutch biotech Northsea Therapeutics has successfully raised $40m (36m) for the development of a fish ... French pharma Genfit also has a candidate
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

The data from the phase 3 JAVELIN Bladder 100 trial has confirmed that Bavencio statistically improves survival in its approved patient population. ... The extension into the earlier indication in bladder cancer is vital for Bavencio, which has been
New efficacy data boosts Aimovig’s migraine market lead

Data from the active treatment phase of STRIVE looked at efficacy and safety of Aimovig (70 and 140 mg) in episodic migraine patients with prior preventive treatment failures. ... Trial data shows that 55% of patients on Aimovig 140 mg experienced at
Merck bulks up in cancer with $2.2bn Peloton buy

The biotech’s first phase 2 trial recruited patients with VHL mutations and is testing PT2977 as a monotherapy, while a second all-comer metastatic RCC trial is pairing the drug ... which has recently seen some late-stage trial failures involving
Realm toppled by second mid-stage trial flop

PR022 did not show the desired effect in this trial,” said Alex Martin, the biotech’s CEO. ... considerably after the twin trial failures.

More from news
Approximately 5 fully matching, plus 30 partially matching documents found.

Latest Intelligence

Interview: AstraZeneca's Susan Galbraith

major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.
An eye towards the biobetter in South Korea

Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. ... Some companies already have their biobetter pipelines in clinical trial stage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

AstraZeneca hires Roche’s Pascal Soriot as CEO

a series of clinical trial failures leading to the departure of AZ's previous CEO Brennan in April, 2012.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Alzheimer’s disease: reviewing the immediate treatment horizon

However, the learnings from these ‘failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years. ... A recent article by BLH Consultant David Cooney explored the bleak

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Principal Medical Writer: Varies on experience

Senior Content Editor - Biotechnology: Salary TBC

Account Management: Competitive Salary Offered

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

PMHub

Add my company

Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....